2X-121 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This 2X-121 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether 2X-121 can convert its Small molecule drug profile and CTNNB x PARP1 x PARP2 x TNKS1 x TNKS2 x Wnt biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | 2X-121 (query alias: 2X-121) |
|---|---|
| Modality / target | Small molecule drug; CTNNB x PARP1 x PARP2 x TNKS1 x TNKS2 x Wnt; CTNNB inhibitors, PARP1 inhibitors, PARP2 inhibitors |
| Highest global status | Phase 2 |
| Originator | Eisai Co., Ltd. |
| Active developers | Allarity Therapeutics, Inc. |
The MCP disease footprint includes Recurrent ovarian cancer, Recurrent Lung Small Cell Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05571969 | Phase 1 | Terminated | 14 | Primary endpoint not disclosed in English source |
| EUCTR2019-002071-34-DK | Phase 2 | Prematurely Ended | 40 | Primary endpoint not disclosed in English source |
| NCT03878849 | Phase 2 | Recruiting | 40 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase Ib, Open Label, Multicenter Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
Phase 1; n=14; evaluation: Not stated in English source. Reported fields: Determination of the MTD of 2X-121 Monotherapy (Number of Subjects With Dose-Limiting Toxicities) = 1 Pts ; Determination of the MTD of 2X-121 Monotherapy (Number of Subjects With Dose-Limiting Toxicities) = 0 Pts
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
Phase 2; n=not disclosed; evaluation: Positive. Reported fields: mOS = exceeds 25 months + months Not Met
Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma.
Phase 1; n=25; evaluation: Not stated in English source. Reported fields: MTD = 600 mg QD
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
2X-121 addresses Recurrent ovarian cancer, Recurrent Lung Small Cell Carcinoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 3 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-06-14 | Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib | Phase 2 | Financial terms not disclosed |
| 2019-04-30 | Dana-Farber Cancer Institute plans to assess Oncology Venture's 2X-121 in a phase II clinical trial for advanced ovarian cancer treatment. | Phase 2 | Financial terms not disclosed |
| 2017-07-07 | Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121 | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Cyclin-dependent kinase (CDK) 12 and/or CDK13 inhibitor combinations and uses thereof”. The milestone feed surfaced a patent-application signal described as “Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor combinations and uses thereof”. The milestone feed surfaced a patent-application signal described as “Application of E7449 or/and Dupilumab in preparation of medicine for treating bone metastasis of lung cancer”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-16. Counts and status fields may change as source records update.
